Immunic AG | WebDisclosure

PRESS RELEASE

published on 06/05/2025 at 12:30, 9 months 21 days ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Immunic completes enrollment for Phase 3 ENSURE trials in Relapsing MS and presents positive Phase 2 CALLIPER trial data in Progressive MS, showcasing vidofludimus calcium's potential. Top-line data in 2026

Immunic Vidofludimus Calcium Phase 3 ENSURE Trials Phase 2 CALLIPER Trial Relapsing MS
BRIEF

published on 06/02/2025 at 12:35, 9 months 24 days ago

Immunic to Attend Key Conferences in June

Biotechnology Conférences Immunic Vidofludimus Calcium Investor Meetings
BRIEF

published on 06/02/2025 at 12:35, 9 months 24 days ago

Immunic participera à des conférences clés en juin

Biotechnologie Conférences Réunions D'investisseurs Immunique Vidofludimus Calcique
PRESS RELEASE

published on 06/02/2025 at 12:30, 9 months 24 days ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June
Immunic, Inc. to participate in multiple investor, scientific, and industry conferences in June 2025, presenting research and clinical pipeline updates

Biotechnology Conférences Scientific Research Immunic Inc. Clinical Pipeline
BRIEF

published on 05/02/2025 at 12:35, 10 months 24 days ago

Immunic to Engage in Key Conferences in May

Clinical Trials Conférences Multiple Sclerosis Immunic Celiac Disease
BRIEF

published on 05/02/2025 at 12:35, 10 months 24 days ago

Immunic participera à des conférences clés en mai

Conférences Essais Cliniques Sclérose En Plaques Immunique Maladie Cœliaque
PRESS RELEASE

published on 05/02/2025 at 12:30, 10 months 24 days ago

Immunic to Participate in Scientific and Industry Conferences in May
Immunic to participate in scientific and industry conferences in May, including DDW and CMSC Annual Meeting 2025, presenting on IMU-856 and vidofludimus calcium for autoimmune diseases

Immunic Autoimmune Diseases Industry Conferences Scientific Conferences IMU-856
BRIEF

published on 04/30/2025 at 13:35, 10 months 25 days ago

Immunic Reports Phase 2 CALLIPER Trial Results for Vidofludimus Calcium

Multiple Sclerosis Vidofludimus Calcium Immunic AG Clinical Trial Results Phase 2 CALLIPER Trial
BRIEF

published on 04/30/2025 at 13:35, 10 months 25 days ago

Immunic annonce les résultats de l'essai de phase 2 CALLIPER pour le vidofludimus calcique

Sclérose En Plaques Immunic AG Résultats Des Essais Cliniques Vidofludimus Calcique Essai CALLIPER De Phase 2
PRESS RELEASE

published on 04/30/2025 at 13:30, 10 months 25 days ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Immunic announces positive results from Phase 2 CALLIPER trial showing 30% reduced risk of disability worsening in Primary Progressive Multiple Sclerosis patients with vidofludimus calcium. Webcast scheduled for April 30

Multiple Sclerosis Immunic Vidofludimus Calcium Phase 2 CALLIPER Trial

Published on 03/26/2026 at 12:59, 4 minutes ago

Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 12:45, 18 minutes ago

Quartz Mountain Reports Strong Warrant Exercise Participation and Provides Exploration Update at Maestro Project, Central British Columbia
Published on 03/26/2026 at 12:45, 18 minutes ago

Electric Royalties Provides Update on Critical Metals Royalty Portfolio
Published on 03/26/2026 at 12:40, 23 minutes ago

Sintana Announces Amendments to its By-Laws
Published on 03/26/2026 at 12:30, 33 minutes ago

Nextech3D.ai Expands Blockchain Ticketing Payments to Apple Pay and Google Pay, Advancing Platform Readiness for Adoption

View all ACCESSWIRE

Published on 03/26/2026 at 12:45, 18 minutes ago

Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. GmbH): Buy
Published on 03/26/2026 at 12:20, 42 minutes ago

North Peak Closes Second and Final Tranche of Previously Announced Non-Brokered Private Placement, Raising Total Funds of $5.675 Million
Published on 03/26/2026 at 12:17, 46 minutes ago

Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 03/26/2026 at 12:05, 58 minutes ago

Artlist Expands Its AI Platform with Professional-Grade AI Music for Video Production
Published on 03/26/2026 at 11:56, 1 hour 7 minutes ago

IVU continues its growth trajectory in the 2025 financial year

View all EQS

Published on 03/26/2026 at 08:57, 4 hours 6 minutes ago

Communiqué Edenred
Published on 03/26/2026 at 08:57, 4 hours 6 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 5 hours 33 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/26/2026 at 07:30, 5 hours 33 minutes ago

BIOPHYTIS ET LYNXKITE INVITÉS À LA CONFÉRENCE NVIDIA : L’IA AU SERVICE DE LA LONGÉVITÉ
Published on 03/25/2026 at 18:53, 18 hours 9 minutes ago

CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026

View all LES ECHOS COMFI WIRE

News